Certificate of Analysis
DOC QC-COA-0412-IPA-5-220-26 · REV 1Triple-tested · Raw material is tested before vialing, the finished vial is tested for sterility, and every lot is released on an independent laboratory certificate.
Test results
| Test | Method | Specification | Result | Verdict |
|---|---|---|---|---|
| Identity | LC-MS | Observed mass conforms to theoretical | Conforms · LC-MS 713.8[M+H] | PASS |
| Purity | HPLC-UV | ≥ 95% | 99.20% | PASS |
| Net content | LC-MS · gravimetric | Report | 4.6 mg | PASS |
Source document
AxisPharm, LLC · Independent analytical laboratory. Reference 27Aug2026-23 · sample received Aug 26, 2026 · reported Aug 24, 2026.
The results above are transcribed from the laboratory's certificate for this lot. Atlas RND hosts a copy of that document; the original is the authority, so open it to confirm every figure.
Conclusion. Lot IPA-5-220-26 of Ipamorelin 5 mg meets the release specification for every test listed above and is approved for distribution for laboratory research use only. Testing performed by AxisPharm, LLC, an independent analytical laboratory, independent of Atlas RND.
www.atlasrnd.co/coa/ipa-5-220-26
LAB REFERENCE 27Aug2026-23